Outlook Therapeutics achieved a landmark regulatory milestone when the U.S. Food and Drug Administration (FDA) officially approved Lytenava (bevacizumab-vikg) as the first and only FDA-approved ophthalmic formulation of bevacizumab specifically indicated for the treatment of wet age-related macular degeneration (wet AMD), securing anticipated multi-year market exclusivity under the Biologics Price Competition and Innovation Act.